Alembic Pharmaceuticals has delivered a resilient performance in the fourth quarter of FY26, reporting a 29% year-on-year surge in net profit as growth across domestic and international businesses boosted overall earnings.

 

The company posted consolidated revenue from operations of Rs 1,848 crore for the quarter ended March 31, 2026, up 4% from the corresponding period last year. Profit after tax rose sharply to Rs 203 crore, while EBITDA before R&D expenses climbed 8% year-on-year to Rs 455 crore, with margins holding firm at 25%.

 

Commenting on the results, Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited, said, “Q4FY26 reflects disciplined execution across our businesses, supported by continued focus on profitability, operational delivery and long-term growth investments. 

 

"We delivered revenue growth across key segments while maintaining healthy pre-R&D operating margins. During the quarter, we marked our entry into the Branded Business in the US, beginning with the launch of Pivya, opening a new avenue for long-term value creation.”

 

A key highlight of the quarter was Alembic’s entry into the US branded pharmaceuticals market through its wholly owned subsidiary, Alembic Therapeutics, with the launch of Pivya.

 

The oral antibiotic is positioned as a first-line treatment for uncomplicated urinary tract infections (uUTIs) in women — a segment that has seen limited innovation over the past decade. The company said the launch marks the first step in building a focused branded specialty portfolio in the United States.

 

Alembic’s India branded business grew 4% year-on-year to Rs 568 crore, driven by solid traction in gynaecology, gastrology, ophthalmology and animal healthcare. The company also introduced two new products during the quarter.

 

Its US formulations business emerged as a major growth driver, rising 11% to Rs 564 crore, supported by six product launches in the US market during the quarter. Ex-US generics revenue stood at Rs 369 crore, while the company secured four ANDA approvals.

 

The API business also posted steady growth, with revenue increasing 2% to Rs 347 crore.

 

For the full FY26 financial year, Alembic reported total revenue from operations of Rs 7,345 crore, marking a 10% increase over FY25.